Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial - 01/04/25
, Ben M Eyck, MD PhD a, *, Bas P L Wijnhoven, ProfMD PhD a, Sjoerd M Lagarde, MD PhD a, Camiel Rosman, ProfMD PhD g, Bo J Noordman, MD PhD a, Maria J Valkema, MD PhD a, Tanya M Bisseling, MD PhD h, Peter-Paul L O Coene, MD PhD i, Marc J van Det, MD PhD k, Jan Willem T Dekker, MD PhD l, Jolanda M van Dieren, MD PhD m, Michail Doukas, MD PhD b, Stijn van Esser, MD PhD l, W Edward Fiets, MD PhD o, Henk H Hartgrink, MD PhD q, Joos Heisterkamp, MD PhD r, I Lisanne Holster, MD PhD j, Bastiaan Klarenbeek, MD PhD g, David van Klaveren, PhD c, Eva Kouw, MD s, Ewout A Kouwenhoven, MD PhD k, Misha D Luyer, ProfMD PhD u, Bianca Mostert, MD PhD d, Grard A P Nieuwenhuijzen, MD PhD u, Liekele E Oostenbrug, MD PhD v, Jean-Pierre Pierie, ProfMD PhD p, Johanna W van Sandick, MD PhD n, Meindert N Sosef, MD PhD w, Manon C W Spaander, ProfMD PhD e, Roelf Valkema, MD PhD f, Edwin S van der Zaag, MD PhD t, Ewout W Steyerberg, ProfPhD x, J Jan B van Lanschot, ProfMD PhD aSANO Study Group†
Summary |
Background |
A substantial proportion of individuals with oesophageal cancer have a pathological complete response after neoadjuvant chemoradiotherapy and oesophagectomy. We aimed to investigate whether active surveillance could be an alternative for individuals with a clinical complete response after neoadjuvant chemoradiotherapy.
Methods |
We performed a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial in 12 Dutch hospitals. Individuals with locally advanced oesophageal cancer and a clinical complete response after neoadjuvant chemoradiotherapy (ie, no tumour detected with endoscopic biopsies, ultrasound, and PET-CT) underwent active surveillance or standard surgery (ie, oesophagectomy within 2 weeks after reaching clinical complete response). There were no inclusion restrictions regarding comorbidities or performance status, but participants had carcinoma, were age 18 years or older, and were treated with curative intent. Randomisation of hospitals was performed using computer-generated sequences without stratification methods, after an initial phase of all hospitals performing standard surgery. The primary endpoint was overall survival, analysed according to a modified intention-to-treat principle (allowing crossover at time of clinical complete response) and an intention-to-treat principle. Non-inferiority was defined as 2-year survival rate for active surveillance of 15% or less below that for standard surgery. The trial was registered within the Netherlands Trial Register, NTR-6803, and the inclusion phase has been completed.
Findings |
Between Nov 8, 2017, and Jan 17, 2021, 1115 individuals were screened, of whom 309 were included. 198 underwent active surveillance and 111 underwent standard surgery. 242 (78%) participants were male and 67 (22%) were female. Median follow-up was 38 months (IQR 32–48). 2-year overall survival for active surveillance (74% [95% CI 69–78]) was non-inferior to standard surgery (71% [62–78]) after modified intention-to-treat analysis (one-sided 95% boundary: 7% lower). It remained non-inferior in the intention-to-treat analysis (75% [68–80] vs 70% [63–77], one-sided 95% boundary: 6% lower). There were no significant differences in overall survival according to modified intention-to-treat analysis (hazard ratio 1·14, two-sided 95% CI 0·74–1·78) or intention-to-treat analysis (0·83, 0·53–1·31). The frequency of postoperative complications and postoperative mortality after standard surgery or postponed surgery after active surveillance was similar between groups.
Interpretation |
Overall survival after active surveillance for oesophageal cancer was non-inferior compared with standard surgery after 2 years. For the long-term efficacy of active surveillance, extended follow-up is required. The results of the present trial could be used for patient counselling and shared decision making.
Funding |
Dutch Cancer Society (KWF) and Netherlands Organisation for Health Research and Development (ZonMw).
Le texte complet de cet article est disponible en PDF.Plan
Vol 26 - N° 4
P. 425-436 - avril 2025 Retour au numéro
Article précédent
- The impact of armed conflict on global patterns of childhood cancer
- Pamela Espinoza, Henry E Rice, Paul H Wise, Nickhill Bhakta, Alexandra Mueller, Taisiya Yakimkova, Lisa M Force, Emily R Smith, Asya Agulnik
- Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
- Ziming Li, Yan Wang, Yuping Sun, Linlin Wang, Xingya Li, Longhua Sun, Zhiyi He, Haiyan Yang, Yongsheng Wang, Qiming Wang, Zhengbo Song, Wei Hong, Yong Wang, Guohao Xia, Yan Yu, Min Peng, Yong Song, Donglin Wang, Rui Meng, Jian Fang, Yongzhong Luo, Wenhua Liang, Sheng Hu, Zhihui Wang, Ke Song, You Li, Lulu Yang, Wei Shi, Shun Lu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?